Year-End Termination Amendment
ERIS GROUP for AMGEN
Firm
Client
Income
$120,000
Expenses
—
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| Year-End Termination | Feb 5, 2008 | $120,000 | Replaced |
| Year-End Termination Amendment (this page) | Feb 14, 2008 | $120,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
S. 1145 and H.R. 1908 - Patent Reform Act of 2007 Intellectual property & process patent issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| DOYLE BARTLETT | N/A |
| JENNIFER BENDALL | N/A |
| SHAYNE GILL | N/A |
| MARK KADESH | COS, SEN. FEINSTEIN |
Health Issues HCR
Follow-On Biologics S. 623 Access to Life-Saving Medicines Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| DOYLE BARTLETT | N/A |
| JENNIFER BENDALL | N/A |
| SHAYNE GILL | N/A |
| MARK KADESH | COS, SEN. FEINSTEIN |
Medicare/Medicaid MMM
S.J. Resolution 22, providing for Congressional Disapproval of a National Coverage Decision restricting Medicare Coverage of Erythropoiesis-Stimulating Agents (ESAs)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DOYLE BARTLETT | N/A |
| JENNIFER BENDALL | N/A |
| SHAYNE GILL | N/A |
| MARK KADESH | COS, SEN. FEINSTEIN |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.